Modem transmission of XXXX values reduces the costs and need for clinic visits.

@entity1 @entity413 @entity6 @entity2412
OBJECTIVE: To determine whether modem technology allows for effective management of type 1 @entity6 when used in lieu of a clinic visit. RESEARCH DESIGN AND METHODS: A total of 70 adolescent @entity1 with @entity6 were prospectively randomized to either a control group or a modem group. Control group @entity1 continued the standard of care of quarterly clinic visits, and modem group @entity1 were instructed to transmit blood @entity413 data every 2 weeks for 6 months instead of a usual quarterly clinic visit. Health care providers analyzed the data received by modem and contacted @entity1 to discuss @entity6 treatment changes. GHbA(1c) levels were determined at 0 and 6 months, and the number of high and low blood @entity413 levels and adverse events were tracked. Clinic visit costs, @entity1 expenses, and health care provider times were tracked for cost analysis for both groups. RESULTS: A total of 63 @entity1 (33 control, 30 modem) completed the 6-month study. The GHbA(1c) values significantly decreased in both groups, with no statistically significant difference between groups (P = 0.96). The occurrence of mild-to-moderate hypoglycemic events were similar in the two groups, and there were no severe hypoglycemic events. The average cost of care for a clinic visit was  305.00, whereas the cost for 6 months of modem transmission was  163.00. CONCLUSIONS: This study shows that electronic transmission of blood @entity413 levels and other @entity6 data every 2 weeks-in lieu of a clinic visit-results in a similar level of @entity413 control and incidence of @entity2412 when compared with current standard care.
